gene exp gapdh hs02758991 g1  (Thermo Fisher)


Bioz Verified Symbol Thermo Fisher is a verified supplier
Bioz Manufacturer Symbol Thermo Fisher manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99
    Name:
    Total Cholesterol Reagents
    Description:
    Determine quantity of cholesterol in serum in vitro with Thermo Scientific Total Cholesterol Reagents
    Catalog Number:
    TR13421
    Price:
    None
    Category:
    Kits and Assays
    Applications:
    Clinical|Diagnostic Testing
    Buy from Supplier


    Structured Review

    Thermo Fisher gene exp gapdh hs02758991 g1
    Scatter plot and correlation analysis between FGF19 and <t>FGF21</t> circulating levels (pg/mL) for diabetic (T2D) and non-diabetic (No-T2D) patients. The FGF19 and FGF21 data for both T2D and No-T2D data were divided into quartiles (Q1, Q2, Q3, and Q4) by using the serum levels of 500 pg/mL for FGF21 and 200 pg/mL for FGF19 as cut offs. The following four classes of patients according to risk for having diabetes were formed: Q1, lowest risk : FGF19 > 200 and FGF21
    Determine quantity of cholesterol in serum in vitro with Thermo Scientific Total Cholesterol Reagents
    https://www.bioz.com/result/gene exp gapdh hs02758991 g1/product/Thermo Fisher
    Average 99 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    gene exp gapdh hs02758991 g1 - by Bioz Stars, 2021-06
    99/100 stars

    Images

    1) Product Images from "Perturbations of Fibroblast Growth Factors 19 and 21 in Type 2 Diabetes"

    Article Title: Perturbations of Fibroblast Growth Factors 19 and 21 in Type 2 Diabetes

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0116928

    Scatter plot and correlation analysis between FGF19 and FGF21 circulating levels (pg/mL) for diabetic (T2D) and non-diabetic (No-T2D) patients. The FGF19 and FGF21 data for both T2D and No-T2D data were divided into quartiles (Q1, Q2, Q3, and Q4) by using the serum levels of 500 pg/mL for FGF21 and 200 pg/mL for FGF19 as cut offs. The following four classes of patients according to risk for having diabetes were formed: Q1, lowest risk : FGF19 > 200 and FGF21
    Figure Legend Snippet: Scatter plot and correlation analysis between FGF19 and FGF21 circulating levels (pg/mL) for diabetic (T2D) and non-diabetic (No-T2D) patients. The FGF19 and FGF21 data for both T2D and No-T2D data were divided into quartiles (Q1, Q2, Q3, and Q4) by using the serum levels of 500 pg/mL for FGF21 and 200 pg/mL for FGF19 as cut offs. The following four classes of patients according to risk for having diabetes were formed: Q1, lowest risk : FGF19 > 200 and FGF21

    Techniques Used:

    Comparison of hepatic gene expression between non-diabetic (No-T2D) and diabetic patients experiencing diabetes remission (T2D-R) or not experiencing diabetes remission (T2D-NoR) after RYGB surgery. Gene expression levels (mRNA determined by real time qPCR) for genes modulating the bile acids-FGF19-FGF21 pathway in the liver were compared between the three aforementioned groups. In the cases of FGF21 ( A ), HNF4α ( B ), CYP7A1 ( C ), β-Klotho ( E ), GS ( F ), and FGFR4 ( G ), the T2D-NoR group of patients displayed signifciantly higher expression levels compared to control (i.e., No-T2D) and/or the T2D-R groups. There were no significant differences between the three groups for SHP ( D ), while, the T2D-R group had signifciantly lower expression levels for HNF4α ( B ), GS ( F ), and FXR ( H ), compared to No-T2D and T2D-NoR. Statistical analysis was performed by using ANOVA followed by Tukey’s test. The different letters (a, b, c) above the bars indicate statistically different groups (significance level at P-value
    Figure Legend Snippet: Comparison of hepatic gene expression between non-diabetic (No-T2D) and diabetic patients experiencing diabetes remission (T2D-R) or not experiencing diabetes remission (T2D-NoR) after RYGB surgery. Gene expression levels (mRNA determined by real time qPCR) for genes modulating the bile acids-FGF19-FGF21 pathway in the liver were compared between the three aforementioned groups. In the cases of FGF21 ( A ), HNF4α ( B ), CYP7A1 ( C ), β-Klotho ( E ), GS ( F ), and FGFR4 ( G ), the T2D-NoR group of patients displayed signifciantly higher expression levels compared to control (i.e., No-T2D) and/or the T2D-R groups. There were no significant differences between the three groups for SHP ( D ), while, the T2D-R group had signifciantly lower expression levels for HNF4α ( B ), GS ( F ), and FXR ( H ), compared to No-T2D and T2D-NoR. Statistical analysis was performed by using ANOVA followed by Tukey’s test. The different letters (a, b, c) above the bars indicate statistically different groups (significance level at P-value

    Techniques Used: Expressing, Real-time Polymerase Chain Reaction

    Comparison of hepatic gene expression between non-diabetic (No-T2D) and diabetic (T2D) patients. Gene expression levels (mRNA determined by real time qPCR) for genes modulating the bile acids-FGF19-FGF21 pathway in the liver were compared between non diabetic and diabetic patients. mRNA levels of FGF21 ( A ), CYP7A1 ( C ), and β-Klotho ( E ) were significantly higher in diabetic patients. There were no significant differences between diabetic and non-diabetic patients for HNF4α ( B ), SHP ( D ), GS ( F ), FGFR4 ( G ), and FXR ( H ). Statistical analysis was performed by using the Student’s T-test (*: P-value
    Figure Legend Snippet: Comparison of hepatic gene expression between non-diabetic (No-T2D) and diabetic (T2D) patients. Gene expression levels (mRNA determined by real time qPCR) for genes modulating the bile acids-FGF19-FGF21 pathway in the liver were compared between non diabetic and diabetic patients. mRNA levels of FGF21 ( A ), CYP7A1 ( C ), and β-Klotho ( E ) were significantly higher in diabetic patients. There were no significant differences between diabetic and non-diabetic patients for HNF4α ( B ), SHP ( D ), GS ( F ), FGFR4 ( G ), and FXR ( H ). Statistical analysis was performed by using the Student’s T-test (*: P-value

    Techniques Used: Expressing, Real-time Polymerase Chain Reaction

    Related Articles

    Transfection:

    Article Title: CEP2 Attenuates Myoblast Differentiation But Does Not Affect Proliferation
    Article Snippet: After 12 hours, when cell confluence reached 50%~60%, the plasmids or siRNA pools were transfected into C2C12 cells using Lipofectamine 2000 transfection reagents (Life Technologies, Shanghai, China) or DharmaFECT siRNA transfection reagents (Thermo Fisher, Guangzhou, China) following the manufacturer's instructions. .. Nucleic acids and transfection reagents were diluted by Opti-MEM I without Serum Medium (Gibco). ..

    Article Title: Systematic Screening of Commonly Used Commercial Transfection Reagents towards Efficient Transfection of Single-Stranded Oligonucleotides
    Article Snippet: The findings will not only contribute to the future In vitro screening of SSO, but also provide references for In vitro delivery of other types of genetic materials such as plasmids and siRNA. .. Transfection Reagents and SSO RNAiMAX transfection reagent (13778030, Invitrogen, Waltham, MA, USA), Lipofectamine 3000 (L3000001, Invitrogen), FuGENE transfection reagent (E2311, Promega, Sydney, Australia), Lipofectamine 2000 reagent (11668027, Invitrogen), Lipofectin reagent (18292011, Invitrogen) were used in this study. .. To evaluate the efficacy of transfection reagents to SSO, a 5′ end FAM labelled 24-mer scrambled ssDNA sequence (5′-FAM-CATCGATGGGAGCTCCGTGTCGTT-3′) was synthesized by Integrated DNA Technologies (IDT, Singapore).

    Article Title: Rheumatoid Arthritis Fibroblast-like Synoviocyte Suppression Mediated by PTEN Involves Survivin Gene Silencing
    Article Snippet: Transient Transfection For in vitro transfections of plasmids, cells were seeded on 6-well plates at a density of 1 × 105 cells per well in medium without antibiotics and cultured until 70 to 80% confluent. .. Before transfection, we optimized the commercial transfection reagents of Opti-MEM | Reduced Serum Medium (Invitrogen Life Technologies, Inc., Carlsbad, CA, USA) and Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. .. The control groups were transfected without plasmid or with pcDNA3.1/U6 vector.

    Article Title: mRNA transfection by a Xentry-protamine cell-penetrating peptide is enhanced by TLR antagonist E6446
    Article Snippet: Transfection of cells with CFTR mRNA Cells were seeded at 4 x 105 cells/well in tissue culture-treated 12-well plates (BD Biosciences, Auckland, NZ) in 1 mL of culture media and cultured overnight. .. Transfection reagents, XP (10 μg) and Lipofectamine™ MessengerMax (3 μL; Thermo Fisher Scientific, Carlsbad, USA), and CFTR mRNA (5 μg) were separately diluted in Opti-MEM I Reduced Serum Medium to 50 μL volumes and incubated for 5–10 min at room temperature. .. Transfection reagent and mRNA solutions were then combined as appropriate and incubated at room temperature for 5 min. Vehicle/DMSO and E6446 were then mixed into these solutions as indicated, the solutions added dropwise to the media in the appropriate wells, and the plates rocked gently by hand to disperse the treatment solutions.

    Article Title: Optimizing Cardiac Delivery of Modified mRNA
    Article Snippet: The mRNA was quantitated by Nanodrop (Thermo Scientific), precipitated with ethanol and ammonium acetate, and resuspended in 10 mM TrisHCl and 1 mM EDTA. .. Different doses of Luc or nGFP mRNA with different nucleotide modifications were transfected into neonatal rat or hPSC-derived CMs using the following different transfection reagents: RNAiMAX or MessengerMAX (Life Technologies), TransIT (Mirus Bio), jetMessenger or JetPEI or Interferin (Polyplus), Dharmacon (GE Healthcare), X-tremeGENE (Roche), or naked with sucrose-citrate buffer. .. The sucrose-citrate buffer contains 20 μL sucrose in nuclease-free water (0.3 g/mL) and 20 μL citrate (0.1 M, pH 7; Sigma) mixed with 20 μL modRNA at different concentrations in saline or only in saline (modRNA at different concentrations in 60 μL saline).

    Article Title: Spin infection for efficient gene delivery in muscle stem cells for intramuscular cell transplantation
    Article Snippet: One day before transfection, Plat-E cells were cultured in DMEM with 10% FBS w/o antibiotics, until they reached 70-90% confluency. .. Various transfection reagents were used, such as: Lipofectamine (Thermo Fisher Scientific, Waltham, MA, USA), Lipofectamine 2000 (Thermo Fisher Scientific), Lipofectamine LTX (Thermo Fisher Scientific), TransIT-293(Mirus Bio LLC, Madison, WI, USA), TransIT-2020 (Mirus Bio LLC), TransIT-LT1 (Mirus Bio LLC), PolyJet (SignaGen Laboratories, Rockville, MD, USA) and LipoJet (SignaGen Laboratories). .. Five μl of each transfection reagent was suspended in 200 μl of DMEM (w/o FBS) with 5 μg of pMX-GFP or pMX-mCherry plasmid DNA for 20 mins at room temperature.

    Article Title: Nemo-like kinase is critical for p53 stabilization and function in response to DNA damage
    Article Snippet: Transient transfections were performed with Lipofectamine 2000 (Invitrogen, Grand Island, NY, USA) according to the manufacturer's instructions (Life Technologies, Inc., Grand Island, NY, USA), as described previously. .. Transfection reagents and DNA were mixed in Opti-MEM (Invitrogen); the complex was added to cells grown to 40–80% confluence, and the cells were cultured for approximately 4 h, after which the medium was replaced with fresh medium. .. For stable transfection with pcDNA3.1 NLK-Flag, 1 mg/ml G418 was added to the medium 48 h after transient transfection, and the cells were selected for 2 weeks.

    In Vitro:

    Article Title: Pharmacological and fasting-induced activation of SIRT1/LXRα signaling alleviates diabetes-induced retinopathy
    Article Snippet: Gradient conditions, peak finding, and quantitation were performed as previously described ( ). .. In vitro Total cholesterol levels were measured using the Amplex Red Cholesterol Assay kit (ThermoFisher Scientific; A12216) according to the manufacturer’s instructions. .. In vitroTotal cholesterol levels were measured using the Amplex Red Cholesterol Assay kit (ThermoFisher Scientific; A12216) according to the manufacturer’s instructions.

    Amplex Red Cholesterol Assay:

    Article Title: Pharmacological and fasting-induced activation of SIRT1/LXRα signaling alleviates diabetes-induced retinopathy
    Article Snippet: Gradient conditions, peak finding, and quantitation were performed as previously described ( ). .. In vitro Total cholesterol levels were measured using the Amplex Red Cholesterol Assay kit (ThermoFisher Scientific; A12216) according to the manufacturer’s instructions. .. In vitroTotal cholesterol levels were measured using the Amplex Red Cholesterol Assay kit (ThermoFisher Scientific; A12216) according to the manufacturer’s instructions.

    Incubation:

    Article Title: mRNA transfection by a Xentry-protamine cell-penetrating peptide is enhanced by TLR antagonist E6446
    Article Snippet: Transfection of cells with CFTR mRNA Cells were seeded at 4 x 105 cells/well in tissue culture-treated 12-well plates (BD Biosciences, Auckland, NZ) in 1 mL of culture media and cultured overnight. .. Transfection reagents, XP (10 μg) and Lipofectamine™ MessengerMax (3 μL; Thermo Fisher Scientific, Carlsbad, USA), and CFTR mRNA (5 μg) were separately diluted in Opti-MEM I Reduced Serum Medium to 50 μL volumes and incubated for 5–10 min at room temperature. .. Transfection reagent and mRNA solutions were then combined as appropriate and incubated at room temperature for 5 min. Vehicle/DMSO and E6446 were then mixed into these solutions as indicated, the solutions added dropwise to the media in the appropriate wells, and the plates rocked gently by hand to disperse the treatment solutions.

    Cell Culture:

    Article Title: Nemo-like kinase is critical for p53 stabilization and function in response to DNA damage
    Article Snippet: Transient transfections were performed with Lipofectamine 2000 (Invitrogen, Grand Island, NY, USA) according to the manufacturer's instructions (Life Technologies, Inc., Grand Island, NY, USA), as described previously. .. Transfection reagents and DNA were mixed in Opti-MEM (Invitrogen); the complex was added to cells grown to 40–80% confluence, and the cells were cultured for approximately 4 h, after which the medium was replaced with fresh medium. .. For stable transfection with pcDNA3.1 NLK-Flag, 1 mg/ml G418 was added to the medium 48 h after transient transfection, and the cells were selected for 2 weeks.

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99
    Thermo Fisher gene exp gapdh hs02758991 g1
    Scatter plot and correlation analysis between FGF19 and <t>FGF21</t> circulating levels (pg/mL) for diabetic (T2D) and non-diabetic (No-T2D) patients. The FGF19 and FGF21 data for both T2D and No-T2D data were divided into quartiles (Q1, Q2, Q3, and Q4) by using the serum levels of 500 pg/mL for FGF21 and 200 pg/mL for FGF19 as cut offs. The following four classes of patients according to risk for having diabetes were formed: Q1, lowest risk : FGF19 > 200 and FGF21
    Gene Exp Gapdh Hs02758991 G1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gene exp gapdh hs02758991 g1/product/Thermo Fisher
    Average 99 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    gene exp gapdh hs02758991 g1 - by Bioz Stars, 2021-06
    99/100 stars
      Buy from Supplier

    Image Search Results


    Scatter plot and correlation analysis between FGF19 and FGF21 circulating levels (pg/mL) for diabetic (T2D) and non-diabetic (No-T2D) patients. The FGF19 and FGF21 data for both T2D and No-T2D data were divided into quartiles (Q1, Q2, Q3, and Q4) by using the serum levels of 500 pg/mL for FGF21 and 200 pg/mL for FGF19 as cut offs. The following four classes of patients according to risk for having diabetes were formed: Q1, lowest risk : FGF19 > 200 and FGF21

    Journal: PLoS ONE

    Article Title: Perturbations of Fibroblast Growth Factors 19 and 21 in Type 2 Diabetes

    doi: 10.1371/journal.pone.0116928

    Figure Lengend Snippet: Scatter plot and correlation analysis between FGF19 and FGF21 circulating levels (pg/mL) for diabetic (T2D) and non-diabetic (No-T2D) patients. The FGF19 and FGF21 data for both T2D and No-T2D data were divided into quartiles (Q1, Q2, Q3, and Q4) by using the serum levels of 500 pg/mL for FGF21 and 200 pg/mL for FGF19 as cut offs. The following four classes of patients according to risk for having diabetes were formed: Q1, lowest risk : FGF19 > 200 and FGF21

    Article Snippet: Pre-designed primers for FGF21 , cholesterol 7 alpha-hydroxylase (CYP7A1 ), fibroblast growth factor receptor 4 (FGF4R ), β-Klotho , farnesoid x receptor (FXR ), Glycogen Synthase (GS ), small heterodimer partner (SHP ), hepatocyte nuclear factor 4α (HNF4α) , and GAPDH were purchased from Applied Biosystems (Hs00173927_m1, Hs00167982_m1, Hs01106908_m1, Hs00545621_m1, Hs00231968_m1, Hs00608677_m1, Hs00222677_m1, Hs00230853_m1, Hs02758991_g1, respectively).

    Techniques:

    Comparison of hepatic gene expression between non-diabetic (No-T2D) and diabetic patients experiencing diabetes remission (T2D-R) or not experiencing diabetes remission (T2D-NoR) after RYGB surgery. Gene expression levels (mRNA determined by real time qPCR) for genes modulating the bile acids-FGF19-FGF21 pathway in the liver were compared between the three aforementioned groups. In the cases of FGF21 ( A ), HNF4α ( B ), CYP7A1 ( C ), β-Klotho ( E ), GS ( F ), and FGFR4 ( G ), the T2D-NoR group of patients displayed signifciantly higher expression levels compared to control (i.e., No-T2D) and/or the T2D-R groups. There were no significant differences between the three groups for SHP ( D ), while, the T2D-R group had signifciantly lower expression levels for HNF4α ( B ), GS ( F ), and FXR ( H ), compared to No-T2D and T2D-NoR. Statistical analysis was performed by using ANOVA followed by Tukey’s test. The different letters (a, b, c) above the bars indicate statistically different groups (significance level at P-value

    Journal: PLoS ONE

    Article Title: Perturbations of Fibroblast Growth Factors 19 and 21 in Type 2 Diabetes

    doi: 10.1371/journal.pone.0116928

    Figure Lengend Snippet: Comparison of hepatic gene expression between non-diabetic (No-T2D) and diabetic patients experiencing diabetes remission (T2D-R) or not experiencing diabetes remission (T2D-NoR) after RYGB surgery. Gene expression levels (mRNA determined by real time qPCR) for genes modulating the bile acids-FGF19-FGF21 pathway in the liver were compared between the three aforementioned groups. In the cases of FGF21 ( A ), HNF4α ( B ), CYP7A1 ( C ), β-Klotho ( E ), GS ( F ), and FGFR4 ( G ), the T2D-NoR group of patients displayed signifciantly higher expression levels compared to control (i.e., No-T2D) and/or the T2D-R groups. There were no significant differences between the three groups for SHP ( D ), while, the T2D-R group had signifciantly lower expression levels for HNF4α ( B ), GS ( F ), and FXR ( H ), compared to No-T2D and T2D-NoR. Statistical analysis was performed by using ANOVA followed by Tukey’s test. The different letters (a, b, c) above the bars indicate statistically different groups (significance level at P-value

    Article Snippet: Pre-designed primers for FGF21 , cholesterol 7 alpha-hydroxylase (CYP7A1 ), fibroblast growth factor receptor 4 (FGF4R ), β-Klotho , farnesoid x receptor (FXR ), Glycogen Synthase (GS ), small heterodimer partner (SHP ), hepatocyte nuclear factor 4α (HNF4α) , and GAPDH were purchased from Applied Biosystems (Hs00173927_m1, Hs00167982_m1, Hs01106908_m1, Hs00545621_m1, Hs00231968_m1, Hs00608677_m1, Hs00222677_m1, Hs00230853_m1, Hs02758991_g1, respectively).

    Techniques: Expressing, Real-time Polymerase Chain Reaction

    Comparison of hepatic gene expression between non-diabetic (No-T2D) and diabetic (T2D) patients. Gene expression levels (mRNA determined by real time qPCR) for genes modulating the bile acids-FGF19-FGF21 pathway in the liver were compared between non diabetic and diabetic patients. mRNA levels of FGF21 ( A ), CYP7A1 ( C ), and β-Klotho ( E ) were significantly higher in diabetic patients. There were no significant differences between diabetic and non-diabetic patients for HNF4α ( B ), SHP ( D ), GS ( F ), FGFR4 ( G ), and FXR ( H ). Statistical analysis was performed by using the Student’s T-test (*: P-value

    Journal: PLoS ONE

    Article Title: Perturbations of Fibroblast Growth Factors 19 and 21 in Type 2 Diabetes

    doi: 10.1371/journal.pone.0116928

    Figure Lengend Snippet: Comparison of hepatic gene expression between non-diabetic (No-T2D) and diabetic (T2D) patients. Gene expression levels (mRNA determined by real time qPCR) for genes modulating the bile acids-FGF19-FGF21 pathway in the liver were compared between non diabetic and diabetic patients. mRNA levels of FGF21 ( A ), CYP7A1 ( C ), and β-Klotho ( E ) were significantly higher in diabetic patients. There were no significant differences between diabetic and non-diabetic patients for HNF4α ( B ), SHP ( D ), GS ( F ), FGFR4 ( G ), and FXR ( H ). Statistical analysis was performed by using the Student’s T-test (*: P-value

    Article Snippet: Pre-designed primers for FGF21 , cholesterol 7 alpha-hydroxylase (CYP7A1 ), fibroblast growth factor receptor 4 (FGF4R ), β-Klotho , farnesoid x receptor (FXR ), Glycogen Synthase (GS ), small heterodimer partner (SHP ), hepatocyte nuclear factor 4α (HNF4α) , and GAPDH were purchased from Applied Biosystems (Hs00173927_m1, Hs00167982_m1, Hs01106908_m1, Hs00545621_m1, Hs00231968_m1, Hs00608677_m1, Hs00222677_m1, Hs00230853_m1, Hs02758991_g1, respectively).

    Techniques: Expressing, Real-time Polymerase Chain Reaction